4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Kalaris Therapeutics, Inc. (KLRS) operates in the Biotechnology industry and is headquartered in Berkeley Heights, United States with about 20 employees. Its market capitalization is roughly $107 million. In the fiscal year ended 2025-12-31, KLRS reported $0M in revenue and ($43M) in net income.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($46M) | ($52M) | ($14M) | ($14M) |
| Net Income | ($43M) | ($69M) | ($15M) | ($16M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($12M) | ($11M) | ($13M) | ($12M) | ($10M) | — |
| Net Income | ($11M) | ($10M) | ($12M) | ($11M) | ($10M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $122M | $6M | $3M | $4M |
| Total Liabilities | $43M | $103M | $48M | $34M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive KLRS viewer.
About TickerBase · Data methodology & sources